Coloplast11.10.21
Coloplast signed an agreement to acquire Atos Medical, a firm specializing in laryngectomy, from Paris private equity firm PAI Partners. Atos Medical is a long-term growth category for Coloplast, and the company gains access to a new chronic care segment to be run as a separate strategic business unit operating on shared Coloplast infrastructure.
The total purchase price for Atos Medical amounts to about $2.5 billion (2.155 billion Euros), and the transaction is expected to close in the firm’s fiscal Q2 2021/22.
“As part of our Strive25 strategy, Coloplast is committed to securing future long-term growth drivers through organic and inorganic initiatives,” said Kristian Villumsen, president and CEO of Coloplast. “Atos Medical is a purpose-driven chronic care business with a mission that fits perfectly with Coloplast. The strategic and financial logic is compelling. I am truly pleased to welcome a new chronic care business into the family with a strong fit to our chronic commercial model—category leadership through innovation, strong relationships with healthcare professionals and a direct-to-consumer set-up.”
“Atos Medical is an undisputed leader in chronic neck stomas care, and we are well-positioned for long-term growth,” said Britt Meelby Jensen, CEO of Atos Medical. “Our companies have comparable business models, and the acquisition will enable us to leverage Coloplast’s strengths to serve more people living with a neck stoma even better than today. Coloplast is a world leading medical device company with an impressive track record. I believe our companies are a great match, and I am confident that together we can accelerate our journey to the benefit of our customers worldwide.”
“We are proud to have been part of Atos Medical’s impressive growth journey under Britt and her team’s inspiring leadership,” said Ragnar Hellenius, PAI Partners. The company’s strong organic growth track-record and industry leading margins are a testimony to its unique direct-to-consumer set-up while also being able to do selective M&A in existing and adjacent segments such as tracheostomy. I feel privileged having had the opportunity to work alongside Atos Medical management and its employees on their quest to improve the quality of life of neck stoma patients.”
The total purchase price for Atos Medical amounts to about $2.5 billion (2.155 billion Euros), and the transaction is expected to close in the firm’s fiscal Q2 2021/22.
“As part of our Strive25 strategy, Coloplast is committed to securing future long-term growth drivers through organic and inorganic initiatives,” said Kristian Villumsen, president and CEO of Coloplast. “Atos Medical is a purpose-driven chronic care business with a mission that fits perfectly with Coloplast. The strategic and financial logic is compelling. I am truly pleased to welcome a new chronic care business into the family with a strong fit to our chronic commercial model—category leadership through innovation, strong relationships with healthcare professionals and a direct-to-consumer set-up.”
“Atos Medical is an undisputed leader in chronic neck stomas care, and we are well-positioned for long-term growth,” said Britt Meelby Jensen, CEO of Atos Medical. “Our companies have comparable business models, and the acquisition will enable us to leverage Coloplast’s strengths to serve more people living with a neck stoma even better than today. Coloplast is a world leading medical device company with an impressive track record. I believe our companies are a great match, and I am confident that together we can accelerate our journey to the benefit of our customers worldwide.”
“We are proud to have been part of Atos Medical’s impressive growth journey under Britt and her team’s inspiring leadership,” said Ragnar Hellenius, PAI Partners. The company’s strong organic growth track-record and industry leading margins are a testimony to its unique direct-to-consumer set-up while also being able to do selective M&A in existing and adjacent segments such as tracheostomy. I feel privileged having had the opportunity to work alongside Atos Medical management and its employees on their quest to improve the quality of life of neck stoma patients.”